Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April July May June August September October November December
Previous Archive
07 July 2023 | Story André Damons | Photo Supplied
Dr Osayande Evbuomwan
Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS), with his certificate after winning the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa.

A research paper by a Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS) has won the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa.

The abstract, by Dr Osayande Evbuomwan, was about evaluating the efficacy of a new nuclear medicine radiopharmaceutical in the identification of active disease in patients with rheumatoid arthritis. It was selected for this award by a special committee at the recently concluded SNMMI 2023 Annual Meeting, which took place between 24 and 27 June in Chicago, USA.

Dr Evbuomwan received the award at the Annual Meeting on 26 June.

“It is a good feeling, and I am proud of the UFS Department of Nuclear Medicine for pulling this off. It is another example that hard work pays,” he says.

Comparing this radiopharmaceutical to ultrasound

Dr Evbuomwan says the research that generated the award-winning abstract was aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. The study concluded that this particular radiopharmaceutical (Tc – 99m glucosamine) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints), and is capable of offering prognostic information in patients with rheumatoid arthritis.

This is the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says. He is currently working on comparisons of this radiopharmaceutical to ultrasound and clinical evaluation in the identification of active disease in patients with rheumatoid arthritis. He says there is also ongoing collaboration with the Rheumatology Division of the Internal Medicine Department, which has played a huge role in making this project fruitful.

“This award is an opportunity to put the department and university on the map, with world stage recognition. We believe that as the Nuclear Medicine Department continues to grow in human resources and equipment, the research output will also increase.”

Dr Gerrit Engelbrecht, Clinical Head of the Department of Nuclear Medicine at the UFS, says the whole department is very proud of Dr Evbuomwan’s accomplishments. “What makes his award even more remarkable is that he outperformed candidates from much larger, highly funded institutions,” he says.

This department announced last year the successful treatment outcome of a patient with metastatic castrate-resistant prostate cancer (MCRPC) – an advanced stage of prostate cancer – by using Lutetium 177 PSMA (Lu-177 PSMA) therapy. This was initially a case of advanced stage prostate cancer, which had failed first-line chemotherapy, leaving little or no other treatment options.

News Archive

Council on Higher Education LLB qualification review not yet complete
2017-05-16

The reaction from various stakeholders following the ‘Outcomes of the National Review of the LLB Qualification’ by the Council on Higher Education (CHE) on 12 April 2017 requires the CHE to clarify that the national review process has not been completed and is ongoing.

The peer-review process conducted under the auspices of the CHE is based on the LLB Standards Document which was developed in 2014-2015 with input from higher-education institutions and the organised legal profession. Following self-review and site visits by peers, the process is now at the point where commendations and shortcomings have been identified, and the statement of 12 April reflects those findings. All law faculties and schools have been asked to improve their LLB programmes to meet the LLB Standard, and no LLB programme has been de-accredited. All institutions retain the accreditation they had before the Review process began and all institutions are working towards retaining their accreditation and improving their LLB programmes.

The South African Law Deans’ Association (SALDA) has issued a set of responses regarding the LLB programme review. The following questions and answers were published to give more clarity on the questions raised.

1.    What is the effect of a finding of conditional accreditation?
The programme remains accredited.

(“Accreditation refers to a recognition status granted to a programme for a stipulated period of time after an HEQC evaluation indicates that it meets minimum standards of quality.”)

The institution must submit a progress report by 6 October 2017 that indicates how short-term aspects raised in the HEQC reports have been addressed and an improvement plan to indicate how longer-term aspects will be addressed.

2.    What is the effect of a finding of notice of withdrawal of accreditation?
The programme remains accredited.

The institution must submit an improvement plan by 6 October 2017 to indicate how the issues raised in the HEQC report will be addressed, including time frames.

3.    How does the finding of notice of withdrawal affect current students?
Students currently enrolled for the LLB programme at any institution are not affected at all. They will graduate with an accredited qualification.

4.    How does the finding of notice of withdrawal affect new applicants?
The programmes remain accredited and institutions may enrol new students as usual. This also includes students completing BA/BCom (Law) programmes who wish to continue with the LLB programme.

5.    How does the finding of notice of withdrawal affect prior graduates?
Degrees previously conferred are not affected.

6.    What happens when the improvement plans are submitted in October 2017?
The CHE will evaluate the plans when they are submitted, and the programmes remain accredited until a decision is taken whether the improvement plan is sufficient and has been fully given effect to or not. The institutions will have to submit progress reports to the CHE indicating implementation of measures contained in the improvement plan.

Should a decision at some stage be taken that a programme’s accreditation must be withdrawn, a teaching-out plan would be implemented so that all enrolled students would have the opportunity to graduate with an accredited degree.

For more information on the CHE’s pronouncement please contact Moleboheng Moshe-Bereng on MosheBerengMF@ufs.ac.za.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept